ReviewAnnual review of pharmacology and toxicology2019
Challenges in Orphan Drug Development: Identification of Effective Therapy for Thyroid-Associated Ophthalmopathy.
Review in Annual review of pharmacology and toxicology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Environmental Triggers and Ocular Disease Networks: Analyzing the Impact of Air Pollutants and Meteorological Factors Using Fuzzy Cognitive Maps.Environment & health (Washington, D.C.) · 2026Article
- Causal relationship between hyperthyroidism and cataracts: a two-sample bi-directional mendelian randomization study.Scientific reports · 2024Article
- Linsitinib inhibits proliferation and induces apoptosis of both IGF-1R and TSH-R expressing cells.Frontiers in immunology · 2024Article
- Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach.Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 2022Article
- 2021 update on thyroid-associated ophthalmopathy.Journal of endocrinological investigation · 2022Review
- PD-L1 Inhibits T Cell-Induced Cytokines and Hyaluronan ExpressionFrontiers in immunology · 2022Article
- Identification of Hub Genes Associated with Nonspecific Orbital Inflammation by Weighted Gene Coexpression Network Analysis.Disease markers · 2022Article
- RhoA with Associated TRAb or FT3 in the Diagnosis and Prediction of Graves' Ophthalmopathy.Disease markers · 2022Article
- Detection and Correlation Analysis of Serum Uric Acid in Patients with Thyroid-Associated Ophthalmopathy.Computational and mathematical methods in medicine · 2022Article
- Integrative metabolic analysis of orbital adipose/connective tissue in patients with thyroid-associated ophthalmopathy.Frontiers in endocrinology · 2022Article
- PRL-1 overexpressed placenta-derived mesenchymal stem cells suppress adipogenesis in Graves' ophthalmopathy through SREBP2/HMGCR pathway.Stem cell research & therapy · 2021Article
- Ocular surface changes in Graves' ophthalmopathy.International journal of ophthalmology · 2021Review
- Insulin-Like Growth Factor Pathway and the Thyroid.Frontiers in endocrinology · 2021Review
- Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy.Expert opinion on investigational drugs · 2020Review
- Human placenta-derived mesenchymal stem cells ameliorate orbital adipogenesis in female mice models of Graves' ophthalmopathy.Stem cell research & therapy · 2019Article
- Human-Derived Organ-on-a-Chip for Personalized Drug Development.Current pharmaceutical design · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Thyroid-associated ophthalmopathy (TAO), the ocular manifestation of Graves' disease, is a process in which orbital connective tissues and extraocular muscles undergo inflammation and remodeling. The condition seems to result from autoimmune responses to antigens shared by the thyroid and orbit. The thyrotropin receptor (TSHR), expressed at low levels in orbital tissues, is a leading candidate antigen. Recent evidence suggests that another protein, the insulin-like growth factor-I receptor (IGF-IR), is overexpressed in TAO, and antibodies against IGF-IR have been detected in patients with the disease. Furthermore, TSHR and IGF-IR form a physical and functional complex, and signaling initiated at TSHR requires IGF-IR activity. Identification of therapy for this rare disease has proven challenging and currently relies on nonspecific and inadequate agents, thus representing an important unmet need. A recently completed therapeutic trial suggests that inhibiting IGF-IR activity with a monoclonal antibody may be an effective and safe treatment for active TAO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.